EGFL7 and neoplasm: Parsatuzumab (MEGF0444A), a humanized monoclonal antibody targeting EGFL7, exhibits immunomodulatory effects and has demonstrated anti-angiogenic activity, tumor growth inhibition, and improved survival in various xenograft and genetically engineered mouse tumor models.